ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 0220 • ACR Convergence 2024

    Ultrasound-assessed Dactylitis as a Biomarker in the Early Diagnosis of Psoriatic Arthritis

    Otto Olivas-Vergara1, Raquel Largo2, Lina Martínez-Estupiñán3, Fredeswinda Romero-Bueno4, Olga Sánchez-Pernaute3, Javier R. Godo3, Maria del Carmen Fariña-Sabaris5, Belen Ruffin Vicente5, Carmen Herencia6, Aránzazu Mediero2, Agustina Criado Alcazar7, Pablo E. Borges1, Sheila Recuero-Díaz1, Andrea Alvear-Torres3, Amalia Gil3, Antía García-Fernández3, Ana Elena Hoyo Fernandez8, M. Isabel Sanchez-Barba8, M. Belen Ortega Trompeta8, Cristina Vazquez-Carballo9, Gabriel Herrero-Beaumont3 and ESPERANZA NAREDO10, 1Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 2Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, 3Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 4Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 5Department of Dermatology.Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 6Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, 7Primary Care..Centro de Salud Paseo Imperial, Madrid, Spain, 8Primary Care.Centro de Salud Paseo Imperial, Madrid, Spain, 9Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz. Autonomous University of Madrid, Madrid, Spain, 10Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

    Background/Purpose: The primary objective of this prospective, longitudinal, observational study was to evaluate the predictive value of ultrasound (US)-detected elementary lesions of dactylitis together with…
  • Abstract Number: 0583 • ACR Convergence 2024

    Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

    Alexis Ogdie1, Philip Mease2, Francois Nantel3, Frederic Lavie4, Mohamed Sharaf5, Emmanouil Rampakakis6, Helena Marzo-Ortega7 and Laure Gossec8, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 3Nantel MedSci Consult, Montreal, QC, Canada, 4Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 5Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 6McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 7NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 8Sorbonne Université, Paris, France

    Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…
  • Abstract Number: 0604 • ACR Convergence 2024

    Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024

    Mahum Mirza1, Jean Liew2, Michael Putman3 and Shikha Singla1, 1Medical College of Wisconsin, Milwaukee, WI, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
  • Abstract Number: 1229 • ACR Convergence 2024

    Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study

    avin maroof1, Nelly Ziade2, Lina El Kibbi3, Bassel Elzorkany4, Nizar Ani5, ASAL ADNAN RIDHA6, Faiq Gorial7, NABAA IHSAN JAWAD AWADH8, Nada Al Chama9, Chafika Haouichat10, Fatima Alnaimat11, Suad Mohamed Abdulla Hannawi12, Suad Hannawi13, Saed Atawnah14, HUSSEIN HALABI15, Manal Al-Mashaleh16, Ahmed Abogamal17, Rachid Bahiri18, Sahar Saad19, maha sabkar20, Krystel Aouad21, Laure Gossec22, Ihsane Hmamouchi23, nabaa abbas24, Elyes Bouajina25, Laila Aljazye26 and Laila ayoub27, and ArLAR-ARCH group, 1University of Kurdistan Hawler, Erbil, Iraq, 2Saint-Joseph University, Beirut, Lebanon, 3Division of rheumatology / Department of Medicine / Specialized Medical Center, Riyadh, Saudi Arabia, 4Private (BZRC), Cairo, Egypt, 5Baghdad College of Medicine, Baghdad, Iraq, 6Baghdad Teaching Hospital, baghdad, Iraq, 7Rheumatology Unit/Department of Medicine/ College of Medicine/ University of Baghdad, Baghdad, Iraq, 8Baghdad Teaching Hospital / Medical City, Baghdad, Iraq, 9Rheumatology Department / Ebn Al Nafiss Hospital / Damascus, Damascus, Syria, 10Djillali Bounaama university hospital, Algiers, Algeria, 11The University of Jordan, amman, Jordan, 12Rheymatology Department / Emirate Health Services / Dubai, Dubai, United Arab Emirates, 13Ministry of Health and Prevention, Dubai, United Arab Emirates, 14Al-Quds University / Alahli Hospital / Hebron ,Palestine, Hebron, Palestinian Territories, 15King Faisal Specialist Hospital / Jeddah, Jeddah, Saudi Arabia, 16Royal Medical Services, Amman, Jordan, 17Dr. Sliman Al Habib Hospital / Al-Azhar Faculty of Medicine, Dubai, United Arab Emirates, 18El Ayachi Hospital / Medical University Hospital / Rabat, Rabat, Morocco, 19King Hamad University Hospital / Assiut Medical School of Egypt, Al Sayh, Bahrain, 20King Hamad university Hospital, Arad, Bahrain, 21Saint George Hospital University Medical Center, Beirut, Lebanon, 22Sorbonne Université, Paris, France, 23Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, 24Baghdad teaching hospital, Medical city, Baghdad, Iraq, Baghdad, Iraq, 25Farhat Hached Hospital of Sousse, Tunisia, Sousse, Tunisia, 26Tripoli / Libya, Tripoli, Libya, 27Rheumatology unit, department of internal medicine, Tripoli Central Hospital. Faculty of Medicine, University of Tripoli, Libya, Tripoli, Libya

    Background/Purpose: Fibromyalgia (FM), a chronic pain disorder, is more prevalent in psoriatic arthritis (PsA) patients, impacting quality of life and potentially leading to unnecessary treatment escalation. Cultural factors may…
  • Abstract Number: 1462 • ACR Convergence 2024

    Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors

    Philip Mease1, Ruizhi Zhao2, Shannon Ferrante3, Natalie J. Shiff4, Pavithra Srinivas5, Soumya Chakravarty6 and Jessica A Walsh7, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Janssen Scientific Affairs, LLC, Titusville, NJ, 3Janssen Scientific Affairs, LLC, Horsham, PA, 4Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, 5Janssen Scientific Affairs LLC, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, 7Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT

    Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…
  • Abstract Number: 1707 • ACR Convergence 2024

    TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease

    Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
  • Abstract Number: 2311 • ACR Convergence 2024

    Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans

    Natalie Anumolu1, Ann Rosenthal1, Katherine Sherman2 and Shikha Singla1, 1Medical College of Wisconsin, Milwaukee, WI, 2Research Division, Zablocki Veterans Affairs, Milwaukee

    Background/Purpose: CPPD has been shown to complicate other types of inflammatory arthritis such as rheumatoid arthritis. However, only a few studies have investigated the correlation…
  • Abstract Number: 2328 • ACR Convergence 2024

    Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?

    Fadi Kharouf1, Virginia Carrizo Abarza2, Shangyi Gao3, Daniel Pereira4, Richard Cook5, Vinod Chandran6 and Dafna Gladman7, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5University of Waterloo, Waterloo, Canada, 6University of Toronto, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
  • Abstract Number: 2345 • ACR Convergence 2024

    Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis

    Andre Lucas Ribeiro1, Virginia Carrizo Abarza2, Dafna Gladman3, Vinod Chandran4 and Lihi Eder5, 1Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, 2Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease where achieving remission remains challenging despite multiple approved biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).…
  • Abstract Number: 2581 • ACR Convergence 2024

    Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study

    Hejian Zou1, Weiguo Wan2, Yu Xue1, Lingyun Sun3, Ning Zhang4, Haiying Chen5, Xiaofei Shi6, Shengyun Liu7, Lin Chen8, Xinmei Ma9, Hua Wei10, Zhenyu Jiang11, Xiaomei Li12, Hongtao Fan13, Hongbin Li14, Jingyang Li15, Rui Wu16, Guixiu Shi17, Jing Zhu18, Xiaodan Kong19, Yuewu Lu20, Xiaojing Cui21, Qianning Zheng21, Xiaoyan Bai22 and Guangchao Dong21, 1Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), 2Huashan Hospital, Fudan University, Shanghai, China (People's Republic), 3Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), 4Shengjing Hospital Affiliated to China Medical University, Shenyang, China (People's Republic), 5The Third Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), 6The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China (People's Republic), 7The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), 8Jilin Province People's Hospital, Changchun, China (People's Republic), 9Zaozhuang Municipal Hospital, Zaozhuang, China (People's Republic), 10Subei People's Hospital of Jiangsu Province, Yangzhou, China (People's Republic), 11The First Hospital of Jilin University, Changchun, China (People's Republic), 12The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China (People's Republic), 13The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), 14Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), 15Zhuzhou Central Hospital, Zhuzhou, China (People's Republic), 16The Tirst Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China (People's Republic), 17The First Affilated Hospital of Xiamen University, Xiamen, China (People's Republic), 18Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), 19The Second Affiliated Hospital of Dalian Medical University, Dalian, China (People's Republic), 20BeiJing Chao-Yang Hospital, Capital Medical University, Beijing, China, 21Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China (People's Republic), 22Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing, China

    Background/Purpose: Patients with psoriasis often develop psoriatic arthritis (PsA), a chronic systemic inflammatory disease with a severe clinical burden that impairs quality of life. In…
  • Abstract Number: 0221 • ACR Convergence 2024

    The Significance of Tenderness with or Without Swelling of Finger Joints in Relation to Magnetic-resonance-imaging, Ultrasound and X-ray in Psoriatic Arthritis

    Victoria Furer1, iris Eshed2, Moshe iluz1, Ori Elkayam3 and Ari Polachek4, 1Tel-Aviv Medical Center, Tel-Aviv, Israel, 2Sheba Medical Center, Tel Hashomer affiliated with School of medicine, Tel Aviv University, Department of Diagnostic Imaging, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 4Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel

    Background/Purpose: The musculoskeletal involvement in psoriatic arthritis (PsA) can involve both articular and extra articular structures manifested by inflammatory and structural lesions. The relationship between…
  • Abstract Number: 0584 • ACR Convergence 2024

    Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry

    Alexis Ogdie1, Nicole Middaugh2, Taylor Blachley2, Tran Bourgeois3, You-Li Ling4, Rajiv Mundayat4, Lara Fallon5, Karim Masri6 and Philip Mease7, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Montreal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Real-world (RW) data on the effectiveness of tofacitinib in patients (pts) with PsA are limited. This study summarized disease activity and pt‑reported outcome measures…
  • Abstract Number: 0606 • ACR Convergence 2024

    Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events

    Bonit Gill1, Jack Geiger1, Jean Liew2, Michael Putman3 and Shikha Singla1, 1Medical College of Wisconsin, Milwaukee, WI, 2Boston University, Boston, MA, 3The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…
  • Abstract Number: 1232 • ACR Convergence 2024

    Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes

    Elizabeth Luce1, Beth schneider2 and Dianna cronin2, 1MyHealthTeam, San Francisco, CA, 2MyHealthTeams, San Francisco, CA

    Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to…
  • Abstract Number: 1463 • ACR Convergence 2024

    Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies

    A. Francesca Setiadi1, Maggie Burhans2, Xuguang Hu2, Stephen Colgan3, Kim Notari2, Marcia C. Teixeira dos Santos2, Apostolos Kontzias2, Sue Cheng2 and Nehal Mehta4, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Amgen, Halton Hills, ON, Canada, 4The George Washington University School of Medicine, Washington, DC

    Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
  • 1
  • 2
  • 3
  • …
  • 81
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology